^
No biomarker
Uveal Melanoma
TC
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
ipilimumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
trametinib
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Uveal Melanoma
CaT
Sensitive: A2 - Guideline
HLA-A2 positive
Uveal Melanoma
IMCgp100
Sensitive: B - Late Trials
HLA-A*02:01 positive
Uveal Melanoma
IMCgp100
Sensitive: B - Late Trials
BRAF V600
Ocular Melanoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600
Ocular Melanoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Ocular Melanoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
GNA11 mutation
Uveal Melanoma
selumetinib
Sensitive: C2 – Inclusion Criteria
GNAQ mutation
Uveal Melanoma
trametinib
Sensitive: C2 – Inclusion Criteria
MBD4 mutation
Uveal Melanoma
nivolumab
Sensitive: C3 – Early Trials
CXCL10 elevation
Uveal Melanoma
IMCgp100
Sensitive: C3 – Early Trials
GNAQ mutation
Uveal Melanoma
pembrolizumab
Sensitive: C3 – Early Trials
GNA11 mutation
Uveal Melanoma
pembrolizumab
Sensitive: C3 – Early Trials
GNA11 Q209L
Uveal Melanoma
IDE196
Sensitive: C3 – Early Trials
LDH-H
Uveal Melanoma
nivolumab
Sensitive: C3 – Early Trials
LDH-H
Uveal Melanoma
pembrolizumab
Sensitive: C3 – Early Trials
GNAQ mutation
Uveal Melanoma
cabozantinib capsule
Sensitive: C3 – Early Trials
GNAQ mutation
Uveal Melanoma
AEB071
Sensitive: C3 – Early Trials
GNA11 mutation
Uveal Melanoma
AEB071
Sensitive: C3 – Early Trials
LDH-H
Uveal Melanoma
ipilimumab
Sensitive: C3 – Early Trials
GNAQ Q209L
Uveal Melanoma
selumetinib
Sensitive: C3 – Early Trials
GNA11 Q209L
Uveal Melanoma
selumetinib
Sensitive: C3 – Early Trials
GNA11 mutation
Uveal Melanoma
cabozantinib capsule
Sensitive: C3 – Early Trials
DDX43 overexpression
Uveal Melanoma
selumetinib
Resistant: C3 – Early Trials
KRAS overexpression
Uveal Melanoma
selumetinib
Resistant: C3 – Early Trials
NRAS overexpression
Uveal Melanoma
selumetinib
Resistant: C3 – Early Trials
PCSK9 underexpression
Uveal Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
IL6 elevation
Uveal Melanoma
IMCgp100
Sensitive: C3 – Early Trials
LDH-L
Uveal Melanoma
pembrolizumab + SNDX-275
Sensitive: C3 – Early Trials
GNAQ G48L + FGFR4 C172G
Uveal Melanoma
trametinib
Sensitive: C4 – Case Studies
MBD4 mutation
Uveal Melanoma
pembrolizumab
Sensitive: C4 – Case Studies
MBD4 L563T
Uveal Melanoma
pembrolizumab + ipilimumab
Sensitive: C4 – Case Studies
GNA11 Q209L
Uveal Melanoma
TAK-733
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
TAK-733
Sensitive: D – Preclinical
GNAQ Q209P
Uveal Melanoma
enzastaurin
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
enzastaurin
Sensitive: D – Preclinical
GNRH1 expression
Uveal Melanoma
zoptarelin doxorubicin
Sensitive: D – Preclinical
CDK9 overexpression
Uveal Melanoma
SNS-032
Sensitive: D – Preclinical
CDK7 overexpression
Uveal Melanoma
SNS-032
Sensitive: D – Preclinical
BAP1 mutation
Uveal Melanoma
JNJ 26481585
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
AEB071
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
trametinib + GSK2126458
Sensitive: D – Preclinical
GNA11 Q209L
Uveal Melanoma
trametinib + GSK2126458
Sensitive: D – Preclinical
GNAQ Q209P
Uveal Melanoma
selumetinib + AZD8055
Sensitive: D – Preclinical
BRAF V600E
Uveal Melanoma
selumetinib + AZD8055
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
selumetinib + AZD8055
Sensitive: D – Preclinical
GNA11 mutation
Uveal Melanoma
AEB071 + AHT956
Sensitive: D – Preclinical
GNAQ mutation
Uveal Melanoma
AEB071 + AHT956
Sensitive: D – Preclinical
GNAQ Q209P
Uveal Melanoma
TAK-733
Sensitive: D – Preclinical
GNAQ Q209P
Uveal Melanoma
trametinib + GSK2126458
Sensitive: D – Preclinical
GNAQ mutation
Uveal Melanoma
Tris DBA
Sensitive: D – Preclinical
GNA11 mutation
Uveal Melanoma
FR900359
Sensitive: D – Preclinical
GNAQ mutation
Uveal Melanoma
FR900359
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
U0126
Sensitive: D – Preclinical
GNAQ Q209P
Uveal Melanoma
selumetinib
Sensitive: D – Preclinical
GNAQ Q209P
Uveal Melanoma
AEB071
Sensitive: D – Preclinical
GNAQ Q209P
Uveal Melanoma
trametinib
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
binimetinib + AEB071
Sensitive: D – Preclinical
GNAQ mutation
Uveal Melanoma
AEB071 + CGM097
Sensitive: D – Preclinical
GNA11 mutation
Uveal Melanoma
binimetinib + AEB071
Sensitive: D – Preclinical
GNA11 mutation
Uveal Melanoma
verteporfin
Sensitive: D – Preclinical
GNAQ mutation
Uveal Melanoma
everolimus + AEB071
Sensitive: D – Preclinical
GNAQ mutation
Uveal Melanoma
binimetinib + AEB071
Sensitive: D – Preclinical
GNA11 mutation
Uveal Melanoma
AEB071 + CGM097
Sensitive: D – Preclinical
GNA11 mutation
Uveal Melanoma
everolimus + AEB071
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
FR900359
Sensitive: D – Preclinical
GNAQ mutation
Uveal Melanoma
JQ-1
Sensitive: D – Preclinical
GNA11 mutation
Uveal Melanoma
JQ-1
Sensitive: D – Preclinical
GNA11 mutation
Uveal Melanoma
PD-0325901 + AEB071
Sensitive: D – Preclinical
GNAQ mutation
Uveal Melanoma
PD-0325901 + AEB071
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
trametinib + hydroxychloroquine
Sensitive: D – Preclinical
GNA11 Q209L
Uveal Melanoma
trametinib + hydroxychloroquine
Sensitive: D – Preclinical
GNAQ Q209P
Uveal Melanoma
trametinib + hydroxychloroquine
Sensitive: D – Preclinical
GNAQ Q209L
Uveal Melanoma
MEK inhibitor + YM-254890
Sensitive: D – Preclinical
CYSLTR2 L129Q
Uveal Melanoma
MEK inhibitor + YM-254890
Sensitive: D – Preclinical
GNAQ R183Q
Uveal Melanoma
MEK inhibitor + YM-254890
Sensitive: D – Preclinical
GNAQ G48V
Uveal Melanoma
MEK inhibitor + YM-254890
Sensitive: D – Preclinical